November 29th, 2024
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announced that the positive phase II clinical study data of HS-10374, an oral, selective, allosteric TYK2 inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis，is presented in a poster presentation at the 19th Annual Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology (CDA 2024) in Wuhan from November 28 to December 1.
The poster and viewing detail are listed below:
The presentation reports the Phase II clinical trial results. HS-10374 showed significant clinical efficacy versus Placebo (PBO) in terms of PASI 75 response rate and sPGA 0/1 response rate with oral doses of 6 mg QD or 12 mg QD in patients with moderate-to-severe plaque psoriasis. The overall safety profile was similar to other TYK2 inhibitors, as adverse events of“skin and subcutaneous disorders” in this study were more commonly reported in PBO group. Ongoing Phase 3 Trial (CTR20243822) with a longer treatment duration and larger populations will further confirm the efficacy and safety of HS-10374 (12mg QD）in such patients.
ABOUT Psoriasis
Psoriasis is a chronic, immune-mediated systemic disease characterized by recurrent inflammation. It is influenced by a combination of genetic predisposition and environmental triggers. The most prevalent form, plaque psoriasis, accounts for approximately 80%–90% of all cases. This condition presents as erythematous, scaly patches or plaques that can range from localized to extensive, affecting varying degrees of body surface area [1]. While psoriasis is not curable, it is a lifelong condition that significantly impacts patients' quality of life, work capacity, and, in severe cases, leads to disability. The disease imposes a substantial burden not only on patients but also on their families and society as a whole. Globally, psoriasis affects 0.14%–1.99% of the population [2]. In China, with a prevalence of 0.50%, an estimated 5 million individuals live with moderate-to-severe cases, highlighting the need for effective management and support [3, 4].
The recommended treatments for patients with moderate-to-severe psoriasis include systemic treatments and/or phototherapy [5]: traditional oral systemic treatments are selected less often for long-term safety concerns; phototherapy is time-consuming and inconvenient; biologics are highly effective, but not all patients respond in the same manner, and some patients have injection fear. There are still unmet medical needs for psoriasis patients, and new therapies should be developed.
[1] 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2023版)[J]. 中华皮肤科杂志, 2023, 56(7): 573-625.
[2] Parisi R, Iskandar I, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study[J]. BMJ, 2020, 369: m1590.
[3] 李慧贤, 胡丽, 郑焱, et al. 基于全球疾病负担(GBD)大数据的中国银屑病流行病学负担分析[J]. 中国皮肤性病学杂志, 2021,35(4):386-392.
[4] 胡煜,顾恒,陈崑.中国中重度银屑病疾病负担和未满足治疗需求的系统综述[J].中华皮肤科杂志,2023,56(10):965-972.
[5] April W, Armstrong, Charlotte, Read. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review [J]. JAMA, 2020,323(19):1945-1960.
